A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
NCT ID: NCT03093116
Last Updated: 2025-07-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
500 participants
INTERVENTIONAL
2017-03-07
2028-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction.
Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of RP-3500, Camonsertib, in Advanced Solid Tumors
NCT04497116
131-I-TM-601 Study in Adults With Solid Tumors
NCT00379132
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
NCT04161391
A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations
NCT05769075
Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors
NCT04678921
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* EXP-1: ROS1 TKI-naïve ROS1+ NSCLC. Up to one prior line of chemotherapy OR immunotherapy is allowed
* EXP-2: 1 Prior ROS1 TKI AND 1 Platinum-based Chemotherapy ROS1+ NSCLC. Disease progression, or intolerant to one prior line of a ROS1 TKI. Must have received one prior line of platinum based chemotherapy OR one prior line of platinum based chemotherapy in combination with immunotherapy before or after a ROS1 TKI
* EXP-3: 2 Prior ROS1 TKIs AND NO Chemotherapy ROS1+ NSCLC. Disease progression, or intolerant to 2 prior lines of a ROS1 TKI treatment. No prior lines of chemotherapy or immunotherapy are allowed.
* EXP-4: 1 Prior ROS1 TKI and NO Chemotherapy or Immunotherapy. Disease progression or intolerant to one prior line of a ROS1 TKI. No prior lines of chemotherapy or immunotherapy are allowed.
* EXP-5: TRK TKI-naïve NTRK+ solid tumors. Any number of prior lines of chemo or immunotherapy is allowed.
* EXP-6: TRK TKI-pretreated NTRK+ solid tumors. Disease progression, or intolerant to 1 or 2 prior TRK TKIs. Any number of prior lines of chemo- or immunotherapy are allowed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Repotrectinib (TPX-0005)
Phase 1
Oral repotrectinib (TPX-0005):
Phase 1a dose escalation, Phase 1b food-effect sub-study, and Phase 1c dose escalation with food, and Midazolam drug-drug interaction sub-study.
Phase 2
Oral repotrectinib (TPX-0005): 6 distinct expansion cohorts
* EXP-1: ROS1 TKI-naïve ROS1+ NSCLC
* EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC
* EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO)
* EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO)
* EXP-5: TRK TKI-naïve NTRK+ solid tumors
* EXP-6: TRK TKI-pretreated NTRK+ solid tumors
Oral repotrectinib (TPX-0005)
Oral repotrectinib (TPX-0005) capsules.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral repotrectinib (TPX-0005)
Oral repotrectinib (TPX-0005) capsules.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. ECOG PS 0-1.
3. Age ≥18 (or age ≥ 20 of age as required by local regulation).
4. Capability to swallow capsules intact (without chewing, crushing, or opening).
5. At least 1 measurable target lesion according to RECIST version 1.1. CNS-only measurable disease as defined by RECIST version 1.1 is allowed.
6. Prior cytotoxic chemotherapy is allowed.
7. Prior immunotherapy is allowed.
8. Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1.
9. Patients with asymptomatic CNS metastases (treated or untreated) and/or asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol specified criteria.
10. Baseline laboratory values fulfilling the following requirements:Absolute neutrophils count (ANC) ≥1500/mm3 (1.5 × 109/L); Platelets (PLTs) ≥100,000/mm3 (100 × 109/L); Hemoglobin ≥ 9.0 g/dL transfusions are allowed; Serum creatinine or creatinine clearance Within normal limits or \> 40 mL/min; Total serum bilirubin \< 1.5 × ULN; Liver transaminases (ASTs/ALTs) \< 2.5 × ULN; \< 5 × ULN if liver metastases are present Alkaline phosphatase (ALP); \< 2.5 × ULN; \< 5 × ULN if liver and/or bone metastasis are present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without supplementation
11. Life expectancy ≥ 3 months.
1. Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) that harbors a ROS1, or NTRK1-3 gene fusion.
2. Subject must have a documented ROS1 or NTRK1-3 gene fusion determined by tissue-based local testing using either:
1. a next-generation sequencing (NGS) or quantitative polymerase chain reaction (qPCR) test will be accepted to determine molecular eligibility.
• Adequate tumor tissue needs to be sent to the Sponsor designated central diagnostic laboratory for retrospective confirmation by a central diagnostic laboratory test selected by the Sponsor.
OR
2. a fluorescence in situ hybridization (FISH) test AND prospective confirmation of fusion status by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment will be accepted to determine molecular eligibility.
* Adequate tumor tissue must be sent to the Sponsor designated central diagnostic laboratory for prospective confirmation by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment.
3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
4. Age ≥12 (or age ≥ 20 as required by local regulation).
5. Willing and able to provide written institutional review board (IRB)/institutional ethics committee-approved Informed Consent or an Assent signed by a parent or legal guardian for subjects age 12 to 17.
6. At least 1 measurable target lesion according to RECIST (v1.1) prospectively confirmed by Blinded Independent Central Radiology Review (BICR), selected by Sponsor, PRIOR to enrollment. Subjects with CNS-only measurable disease ≥10 mm as defined by RECIST (v1.1) are eligible.
Exclusion Criteria
8. Subjects with asymptomatic CNS metastases (treated or untreated) and/or asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol specified criteria.
9. Baseline laboratory values fulfilling the following requirements:Absolute neutrophils count (ANC) ≥1500/mm3 (1.5 × 109/L); Platelets (PLTs) ≥100,000/mm3 (100 × 109/L); Hemoglobin ≥ 9.0 g/dL transfusions are allowed; Serum creatinine or creatinine clearance \> 40 mL/min; Total serum bilirubin \< 1.5 × ULN; Liver transaminases (ASTs/ALTs) \< 2.5 × ULN; \< 5 × ULN if liver metastases are present Alkaline phosphatase (ALP); \< 2.5 × ULN; \< 5 × ULN if liver and/or bone metastasis are present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without supplementation
10. Life expectancy ≥ 3 months.
1. Concurrent participation in another therapeutic clinical trial.
2. Symptomatic brain metastases or leptomeningeal involvement.
3. History of previous cancer, except for squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected, requiring therapy within the previous 2 years.
4. Major surgery within 4 weeks of start of repotrectinib treatment. Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry. Palliative radiation (≤10 fractions) must have been completed at least 48 hours prior to study entry
5. Clinically significant cardiovascular disease (either active or within 6 months prior to enrollment): myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (New York Heart Association Classification Class ≥ II), cerebrovascular accident or transient ischemic attack, symptomatic bradycardia, requirement for anti-arrhythmic medication. Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2
6. Any of the following cardiac criteria:
Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTcF) \> 470 msec obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval \> 250 msec) Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval.
7. Known active infections (bacterial, fungal, viral including HIV positivity).
8. Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption.
9. Peripheral neuropathy of CTCAE ≥grade 2.
10. History of extensive, disseminated, bilateral, or presence of CTCAE grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis. Subjects with history of prior radiation pneumonitis are not excluded.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zai Lab (Shanghai) Co., Ltd.
INDUSTRY
Turning Point Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 2129
Duarte, California, United States
Local Institution - 2120
Glendale, California, United States
Local Institution - 2136
La Jolla, California, United States
Local Institution - 2114
La Jolla, California, United States
Local Institution - 2121
Long Beach, California, United States
Local Institution - 2101
Orange, California, United States
University of California Irvine Medical Center
Orange, California, United States
Local Institution - 2126
Santa Rosa, California, United States
Local Institution - 1003
Aurora, Colorado, United States
Local Institution - 2103
Aurora, Colorado, United States
Local Institution - 2106
Washington D.C., District of Columbia, United States
Local Institution - 2110
Washington D.C., District of Columbia, United States
Local Institution - 2128
Hollywood, Florida, United States
Local Institution - 2113
Tampa, Florida, United States
Local Institution - 2139
Athens, Georgia, United States
Local Institution - 2134
Columbus, Georgia, United States
Local Institution - 2125
Chicago, Illinois, United States
Local Institution - 2142
Peoria, Illinois, United States
Local Institution - 2116
New Orleans, Louisiana, United States
Local Institution - 2133
Baltimore, Maryland, United States
Local Institution - 2104
Boston, Massachusetts, United States
Local Institution - 1004
Boston, Massachusetts, United States
Local Institution - 2131
Boston, Massachusetts, United States
Local Institution - 2105
Ann Arbor, Michigan, United States
Local Institution - 2111
Detroit, Michigan, United States
Local Institution - 2140
Detroit, Michigan, United States
Local Institution - 2132
Saint Paul, Minnesota, United States
Local Institution - 2147
Bolivar, Missouri, United States
Local Institution - 2115
St Louis, Missouri, United States
Local Institution - 2122
New Brunswick, New Jersey, United States
Local Institution - 2117
New York, New York, United States
Local Institution - 2102
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Local Institution - 2144
Goldsboro, North Carolina, United States
Local Institution - 2112
Canton, Ohio, United States
Local Institution - 2143
Cincinnati, Ohio, United States
Local Institution - 2109
Cleveland, Ohio, United States
Local Institution - 2123
Columbus, Ohio, United States
Local Institution - 2119
Toledo, Ohio, United States
Local Institution - 2108
Philadelphia, Pennsylvania, United States
Local Institution - 2148
Memphis, Tennessee, United States
Local Institution - 2130
Dallas, Texas, United States
Local Institution - 2127
Houston, Texas, United States
Local Institution - 2138
Houston, Texas, United States
Local Institution - 2146
Kingwood, Texas, United States
Local Institution - 2137
Fairfax, Virginia, United States
Local Institution - 2107
Seattle, Washington, United States
Local Institution - 2141
Tacoma, Washington, United States
Local Institution - 2145
Appleton, Wisconsin, United States
Local Institution - 6102
Camperdown, New South Wales, Australia
Local Institution - 6103
Adelaide, South Australia, Australia
Local Institution - 6101
Melbourne, Victoria, Australia
Local Institution - 3301
East Melbourne, , Australia
Local Institution - 4802
Antwerp, , Belgium
Local Institution - 4801
Leuven, , Belgium
Local Institution - 2202
Edmonton, Alberta, Canada
Local Institution - 2205
Vancouver, British Columbia, Canada
Local Institution - 2201
Toronto, Ontario, Canada
Local Institution - 6503
Toronto, Ontario, Canada
Local Institution - 2203
Ontario, , Canada
Local Institution - 2204
Ottawa, , Canada
Local Institution - 6702
Beijing, Beijing Municipality, China
Beijing Cancer hospital
Beijing, Beijing Municipality, China
Daping Hospital, the Third Affiliated Hospital of Third Military Medical University /Cancer Center
Daping, Chongqing Municipality, China
Local Institution - 6719
Fuzhou, Fujian, China
The First Affiliated hospital of Xiamen University-oncology
Xiamen, Fujian, China
Guangdong Provincial People'S Hospital
Guangzhou, Guangdong, China
Local Institution - 6733
Guangzhou, Guangdong, China
Local Institution - 6505
Shenzhen, Guangdong, China
The Affiliated Tumor Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Local Institution - 6504
Shatin, HONG KONG, China
Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology/Cancer Center Department
Wuhan, Hubei, China
Local Institution - 6705
Changsha, Hunan, China
Hunan Cancer Hospital-thoracic oncology II
Changsha, Hunan, China
Local Institution - 6748
Nanjing, Jiangsu, China
XuZhou Central Hospital/Oncology Department
Xuzhou, Jiangsu, China
Jilin Cancer Hospital/Medical Oncology Department
Changchun, Jilin, China
Jilin Cancer Hospital/Medical Oncology Department
Changchun, Jilin, China
The first hospital of Jilin university-Oncology Department
Changchun, Jilin, China
Liaoning Cancer Hospital
Shenyang, Liaoning, China
Tangdu Hospital
Xi'an, Shan3xi, China
Shanxi Bethune Hospital
Taiyuan, Shanxi, China
Sichuan Cancer Hospital/Medical Oncology Department
Chengdu, Sichuan, China
The First Hospital Affiliated To AMU - Southwest Hospital
Chongqing, Sichuan, China
Local Institution - 6725
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital-Oncology
Hangzhou, Zhejiang, China
The Third Xiangya Hospital of Central South University/Department of Respiratory and Critical Care Medicine
Changsha, , China
West China Hospital Sichuan University/Lung cancer center
Chengdu, , China
The First Affiliated Hospital - Zhejiang University School of Medicine
Hangzhou, , China
Anhui Provincial Hospital
Hefei, , China
Shanghai Chest Hospital
Shanghai, , China
Shanghai Chest Hospital
Shanghai, , China
Weifang People's Hospital/Medical Oncology Department
Weifang, , China
Henan Cancer Hospital/The 1st pneumology department
Zhengzhou, , China
Local Institution - 4901
Copenhagen, , Denmark
Local Institution - 4201
Marseille, Bouches-du-Rhône, France
Local Institution - 4207
Brest, , France
Local Institution - 4204
Dijon, , France
Local Institution - 4206
Grenoble, , France
Centre Antoine-Lacassagne
Nice, , France
Chu Poitiers
Poitiers, , France
Local Institution - 4203
Saint-Mandé, , France
Institute Gustave Roussy
Villejuif, , France
Local Institution - 4704
Berlin, , Germany
Local Institution - 4701
Cologne, , Germany
Local Institution - 4703
Dresden, , Germany
Local Institution - 4702
Heidelberg, , Germany
Local Institution - 6502
Hong Kong, , Hong Kong
Local Institution - 6501
Hong Kong, , Hong Kong
Local Institution - 5101
Budapest, , Hungary
Local Institution - 5103
Budapest, , Hungary
Local Institution - 4301
Milan, MI, Italy
Local Institution - 4306
Milan, , Italy
Local Institution - 4307
Palermo, , Italy
Local Institution - 4303
Pordenone, , Italy
Local Institution - 4304
Ravenna, , Italy
Local Institution - 4305
Reggio Emilia, , Italy
Local Institution - 4308
Roma, , Italy
Local Institution - 4302
Terni, , Italy
Ehime University Hospital
Tōon, Ehime, Japan
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
Kanagawa cancer center
Yokohama, Kanagawa, Japan
Osaka City General Hospital
Osaka, Osaka, Japan
National Cancer Center Hospital.
Chuo-ku, Tokyo, Japan
Tottori University Hospital
Yonago, Tottori, Japan
National Cancer Center Hospital East
Kashiwa, , Japan
Nagoya University Hospital
Nagoya, , Japan
Osaka International Cancer institute
Osaka, , Japan
Local Institution - 4502
Amsterdam, , Netherlands
Local Institution - 4501
Groningen, , Netherlands
Ośrodek Badań Klinicznych Wczesnych Faz, Uniwersyteckie Centrum Kliniczne
Gdansk, , Poland
Local Institution - 4604
Lublin, , Poland
Local Institution - 4605
Poznan, , Poland
Local Institution - 4603
Szczecin, , Poland
Local Institution - 4602
Warsaw, , Poland
Local Institution - 6401
Singapore, , Singapore
Local Institution - 6402
Singapore, , Singapore
Local Institution - 3003
Seoul, Gangnam-gu, South Korea
Local Institution - 6308
Hwasun-eup, Hwasun-gun, Jeollanam-do, South Korea
Yonsei University Health System
Seoul, Seodaemun-gu, South Korea
Local Institution - 3002
Seoul, Seoul Teugbyeolsi, South Korea
Local Institution - 6301
Seoul, Seoul-teukbyeolsi [Seoul], South Korea
Local Institution - 6303
Seoul, Seoul-teukbyeolsi [Seoul], South Korea
Local Institution - 6306
Cheongju-si, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Local Institution - 6302
Seoul, , South Korea
Local Institution - 6307
Seoul, , South Korea
Local Institution - 6305
Seoul, , South Korea
Local Institution - 6304
Seoul, , South Korea
Local Institution - 4102
Barcelona, , Spain
Local Institution - 4101
Barcelona, , Spain
Local Institution - 4106
Madrid, , Spain
Local Institution - 4104
Madrid, , Spain
Local Institution - 4103
Madrid, , Spain
Local Institution - 4105
Madrid, , Spain
Clinica Universidad de Navarra
Pamplona, , Spain
Instituto Valenciano de Oncología (IVO) - Unidad de Investigación Clínica FINCIVO
Valencia, , Spain
Local Institution - 6201
Taiepi, , Taiwan
Local Institution - 6203
Tainan City, , Taiwan
Local Institution - 6202
Taipei, , Taiwan
Local Institution - 4401
London, , United Kingdom
Local Institution - 4402
London, , United Kingdom
Local Institution - 4404
London, , United Kingdom
Local Institution - 4403
Manchester, , United Kingdom
Local Institution - 4405
Sutton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
BMS Study Connect Contact Center www.BMSStudyConnect.com
Role: CONTACT
First line of the email MUST contain the NCT# and Site #.
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Misako Nagasaka, Site 1001
Role: primary
Site 1003
Role: primary
Site 2116
Role: primary
Site 1004
Role: primary
Alexander Drilon, Site 1002
Role: primary
Jian Fang, Site 6703
Role: primary
Yong He, Site 6736
Role: primary
Jingxun Wu, Site 6708
Role: primary
Jinji Yang, Site 6747
Role: primary
Yan Yu, Site 6722
Role: primary
Xiaorong Dong, Site 6710
Role: primary
Nong Yang, Site 6718
Role: primary
Xiang Wang, Site 6732
Role: primary
Meili Sun, Site 6720
Role: primary
Ying Cheng, Site 6717
Role: primary
Jiuwei Cui, Site 6714
Role: primary
Rui Ma, Site 6742
Role: primary
Haichuan Su, Site 6754
Role: primary
Junping Zhang, Site 6749
Role: primary
Wenxiu Yao, Site 6728
Role: primary
Liang Gong, Site 6716
Role: primary
Yiping Zhang, Site 6721
Role: primary
Jie Meng, Site 6734
Role: primary
Feng Luo, Site 6724
Role: primary
Jianying Zhou, Site 6712
Role: primary
Yueyin Pan, Site 6704
Role: primary
Liyan Jiang, Site 6709
Role: primary
Shun Lu, Site 6701
Role: primary
Guohua Yu, Site 6727
Role: primary
Xiufeng Hu, Site 6715
Role: primary
Esma Saada-Bouzid, Site 4205
Role: primary
Nicolas Isambert, Site 4208
Role: primary
Benjamin Besse, Site 4202
Role: primary
Site 4304
Role: primary
Naoyuki Nogami, Site 6609
Role: primary
Jun Sakakibara, Site 6607
Role: primary
Kato Terufumi, Site 6603
Role: primary
Haruko Daga, Site 6605
Role: primary
Yasushi Goto, Site 6604
Role: primary
Kodani Masahiro, Site 6606
Role: primary
Koichi Goto, Site 6601
Role: primary
Yuichi Ando, Site 6608
Role: primary
Motohiro 基裕 Tamiya 田宮, Site 6602
Role: primary
Rafal Dziadziuszko, Site 4601
Role: primary
Byoung Chul Cho, Site 3002
Role: primary
Dong-Wan Kim, Site 3001
Role: primary
Ignacio Gil Bazo, Site 4108
Role: primary
Angel Guerrero, Site 4107
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299.
Yun MR, Kim DH, Kim SY, Joo HS, Lee YW, Choi HM, Park CW, Heo SG, Kang HN, Lee SS, Schoenfeld AJ, Drilon A, Kang SG, Shim HS, Hong MH, Cui JJ, Kim HR, Cho BC. Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naive and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 Jul 1;26(13):3287-3295. doi: 10.1158/1078-0432.CCR-19-2777. Epub 2020 Apr 8.
Drilon A, Ou SI, Cho BC, Kim DW, Lee J, Lin JJ, Zhu VW, Ahn MJ, Camidge DR, Nguyen J, Zhai D, Deng W, Huang Z, Rogers E, Liu J, Whitten J, Lim JK, Stopatschinskaja S, Hyman DM, Doebele RC, Cui JJ, Shaw AT. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. Cancer Discov. 2018 Oct;8(10):1227-1236. doi: 10.1158/2159-8290.CD-18-0484. Epub 2018 Aug 9.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CA127-1024
Identifier Type: OTHER
Identifier Source: secondary_id
TPX-0005-01
Identifier Type: OTHER
Identifier Source: secondary_id
CA127-1024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.